Currently out of the existing stock ratings of Joshua Jennings, 180 are a BUY (86.12%), 29 are a HOLD (13.88%).

Joshua Jennings

Work Performance Price Targets & Ratings Chart

Analyst Joshua Jennings, currently employed at TD COWEN, carries an average stock price target met ratio of 53.83% that have a potential upside of 27.89% achieved within 247 days. Previously, Joshua Jennings worked at COWEN.

Joshua Jennings’s has documented 422 price targets and ratings displayed on 32 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on BSX, Boston Scientific Corp at 12-Dec-2024.

Wall Street Analyst Joshua Jennings

Analyst best performing recommendations are on DCBO (DOCEBO).
The best stock recommendation documented was for DCBO (DOCEBO) at 3/10/2023. The price target of $39 was fulfilled within 4 days with a profit of $3.58 (10.11%) receiving and performance score of 25.27.

Average potential price target upside

of $37.8 (34.86%) on JNJ (JOHNSON & JOHNSON).
of $35.87 (29.68%) on DXCM (DEXCOM).
of $32.61 (17.08%) on SYK (STRYKER).

ABT Abbott Laboratories BAX Baxter International BSX Boston Scientific Corp ESTA Establishment Labs Holdings EW Edwards Lifesciences Corp GILD Gilead Sciences HUMA Humacyte JNJ Johnson & Johnson MDT Medtronic PLC NUVA NuVasive OM Outset Medical SYK Stryker TMDX TransMedics Group ZBH Zimmer Biomet Holdings ATEC Alphatec Holdings CERS Cerus APEN Apollo Endosurgery ITMR Itamar Medical Ltd PROF Profound Medical Corp AZYO Aziyo Biologics QTNT Quotient Ltd TNDM Tandem Diabetes Care DXCM DexCom STXS Stereotaxis MDWD Mediwound Ltd BDX Becton Dickinson and Company BFLY Butterfly Network CTSO Cytosorbents Crp PRCT Procept Biorobotics Corp RBOT Vicarious Surgical . DCBO Docebo PODD Insulet

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Matt Miksic (BARCLAYS)